Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jorge Cortes

Showing results (241-250 of 791) with videos related to

Pageof 80
Sort By:
American Journal of Hematology|September 25, 2014
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experienceNaveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|March 22, 2015
Secondary mutations as mediators of resistance to targeted therapy in leukemiaNaval Daver, Jorge Cortes, Farhad Ravandi, et al.
Cancer|February 25, 2003
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
British Journal of Haematology|October 5, 2019
Sudden blastic transformation in treatment-free remission chronic myeloid leukaemiaMansour Alfayez, Guillaume Richard-Carpentier, Elias Jabbour, et al.
Cancer|February 29, 2012
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyHagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
American Journal of Hematology|January 13, 2015
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting SystemJorge Cortes, Michael Mauro, Juan Luis Steegmann, et al.
Leukemia Research|March 22, 2003
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AMLElihu Estey, Francis Giles, Jorge Cortes, et al.
American Journal of Hematology|January 10, 2012
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemiaAlireza Eghtedar, Gautam Borthakur, Farhad Ravandi, et al.
Journal of Geriatric Oncology|July 15, 2025
Age-related disparities in survival following colorectal cancer diagnosis in an underserved community in Georgia: A retrospective cohort analysisMeng-Han Tsai, Jorge Cortes, Elinita Pollard, et al.
Pageof 80

Showing results (241-250 of 791) with videos related to

Sort By:
Pageof 80
American Journal of Hematology|September 25, 2014
Improving outcomes for patients with acute myeloid leukemia in first relapse: a single center experienceNaveen Pemmaraju, Hagop Kantarjian, Guillermo Garcia-Manero, et al.
Blood|March 22, 2015
Secondary mutations as mediators of resistance to targeted therapy in leukemiaNaval Daver, Jorge Cortes, Farhad Ravandi, et al.
Cancer|February 25, 2003
Increased telomerase activity is associated with shorter survival in patients with chronic phase chronic myeloid leukemiaSrdan Verstovsek, Hagop Kantarjian, Taghi Manshouri, et al.
British Journal of Haematology|October 5, 2019
Sudden blastic transformation in treatment-free remission chronic myeloid leukaemiaMansour Alfayez, Guillaume Richard-Carpentier, Elias Jabbour, et al.
Cancer|February 29, 2012
Very long-term follow-up results of imatinib mesylate therapy in chronic phase chronic myeloid leukemia after failure of interferon alpha therapyHagop Kantarjian, Susan O'Brien, Guillermo Garcia-Manero, et al.
Blood|September 23, 2006
Dasatinib (BMS-354825) is active in Philadelphia chromosome-positive chronic myelogenous leukemia after imatinib and nilotinib (AMN107) therapy failureAlfonso Quintas-Cardama, Hagop Kantarjian, Dan Jones, et al.
American Journal of Hematology|January 13, 2015
Cardiovascular and pulmonary adverse events in patients treated with BCR-ABL inhibitors: Data from the FDA Adverse Event Reporting SystemJorge Cortes, Michael Mauro, Juan Luis Steegmann, et al.
Leukemia Research|March 22, 2003
Empirical examination of the neutrophil criterion (>1500 microl(-1)) currently needed to declare CR in AMLElihu Estey, Francis Giles, Jorge Cortes, et al.
American Journal of Hematology|January 10, 2012
Characteristics of translocation (16;16)(p13;q22) acute myeloid leukemiaAlireza Eghtedar, Gautam Borthakur, Farhad Ravandi, et al.
Journal of Geriatric Oncology|July 15, 2025
Age-related disparities in survival following colorectal cancer diagnosis in an underserved community in Georgia: A retrospective cohort analysisMeng-Han Tsai, Jorge Cortes, Elinita Pollard, et al.
Pageof 80